Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,799,482
  • Shares Outstanding, K 691,568
  • Annual Sales, $ 620 K
  • Annual Income, $ -583,200 K
  • 60-Month Beta 1.16
  • Price/Sales 7,827.39
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade IBRX with:

Options Overview Details

View History
  • Implied Volatility 119.50% ( +0.59%)
  • Historical Volatility 164.56%
  • IV Percentile 46%
  • IV Rank 14.79%
  • IV High 424.99% on 10/18/23
  • IV Low 66.49% on 12/15/23
  • Put/Call Vol Ratio 0.11
  • Today's Volume 6,716
  • Volume Avg (30-Day) 37,487
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 232,311
  • Open Int (30-Day) 282,141

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +39.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.79 +45.51%
on 04/24/24
10.53 -33.81%
on 04/29/24
+1.48 (+26.96%)
since 04/23/24
3-Month
3.75 +85.87%
on 02/26/24
10.53 -33.81%
on 04/29/24
+3.47 (+99.14%)
since 02/23/24
52-Week
1.25 +457.60%
on 10/19/23
10.53 -33.81%
on 04/29/24
+4.18 (+149.82%)
since 05/23/23

Most Recent Stories

More News
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

/CNW/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of...

BIOV.CN : 0.0700 (unch)
BVAXF : 0.0580 (-6.45%)
MRNA : 161.05 (-1.39%)
BOLD : 11.02 (+0.27%)
IBRX : 6.97 (+0.43%)
MGNX : 4.61 (-1.91%)
Promising Outlook as Biotech Sector Advances Cancer Treatments Amidst Rising Diagnoses

USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society...

BRX : 22.28 (+0.18%)
BIOV.CN : 0.0700 (unch)
BVAXF : 0.0580 (-6.45%)
MRNA : 161.05 (-1.39%)
BOLD : 11.02 (+0.27%)
IBRX : 6.97 (+0.43%)
MGNX : 4.61 (-1.91%)
Biotech Sector Advances in Pancreatic Cancer Research

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working...

BRX : 22.28 (+0.18%)
ONCY : 1.1099 (+0.90%)
ONC.TO : 1.49 (-1.32%)
NVS : 102.17 (+0.21%)
IBRX : 6.97 (+0.43%)
ACRS : 1.1900 (+3.48%)
NUVB : 3.29 (+0.30%)
Biotech’s Role in Addressing the Pancreatic Cancer Emergency

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END

NVX : 2.18 (-7.63%)
ONCY : 1.1099 (+0.90%)
ONC.TO : 1.49 (-1.32%)
NVS : 102.17 (+0.21%)
IBRX : 6.97 (+0.43%)
ACRS : 1.1900 (+3.48%)
NUVB : 3.29 (+0.30%)
Should You Still Buy the Nasdaq's Best-Performing October Stocks?

Last month's big winners were tricky to handle due to the amount of speculation investors were willing to do with them.

COMP : 4.25 (+1.19%)
GPCR : 37.00 (+1.70%)
IBRX : 6.97 (+0.43%)
OLK : 23.99 (-0.19%)
Why Shares of ImmunityBio Jumped This Week

The company's founder is spending his own money to help finance the business's efforts.

IBRX : 6.97 (+0.43%)
SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 29, 2023 in the Class Action Filed on Behalf of ImmunityBio, Inc. (IBRX) Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX)...

IBRX : 6.97 (+0.43%)
SHAREHOLDER ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc.(IBRX) Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) of a class action securities...

IBRX : 6.97 (+0.43%)
IBRX FINAL DEADLINE TUESDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important August 29 Deadline in Securities Class Action - IBRX

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23,...

IBRX : 6.97 (+0.43%)
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

IBRX : 6.97 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 7.70
2nd Resistance Point 7.44
1st Resistance Point 7.19
Last Price 6.97
1st Support Level 6.68
2nd Support Level 6.42
3rd Support Level 6.17

See More

52-Week High 10.53
Fibonacci 61.8% 6.99
Last Price 6.97
Fibonacci 50% 5.89
Fibonacci 38.2% 4.79
52-Week Low 1.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar